Skip to main content

Our Center News

UCSD Center of Excellence is Enrolling Participants for our KINECT-HD Neurocrine Study

Our site is currently looking for participants to enroll in our KINECT-HD Neurocrine study which is investigating the efficacy of the drug Valbenazine to reduce HD associated chorea. Valbenazine has been studied and approved by the FDA to treat tardive diskynesia but is undergoing further review to ensure its safety in Huntington's patients. The study is done over a 4 month period where we will be tracking your dosing as well as cognitive and motoric progression after starting the medication. Please call or email us as soon as possible if you're interested in finding out if you qualify for this clinical trial! 

The HDCRC is on Social Media

UCSD Huntington's Disease Clinical Research Center has recently become much more active on Twitter and Facebook! While we try our best to update this webpage regularly, we fell that we're able to reach more people through social media as compared to here. While this webpage continues to serve as a great place to read in more depth about our clinical trials as well as to access important resources and information, our social media channels are more frequently updated so that we can get details out to our community much faster.

Follow us: 

Prilenia's PROOF-HD Starting Here at UCSD HD Research Center

Prilenia Therapeutics' PROOF-HD phase 3 clinical trial has begun its first round of baseline visits here at UC San Diego's CoE. The PROOF-HD study aims to study the efficacy of the drug Pridopidine to confirm pervious findings that pridopidine demonstrated maintenance of functional capacity in early HD patients. The trial is a randomized, double-blind study, meaning that if the trial meets its predetermined clinical end points, Prilenia may try to put the drug to market quickly after the conclusion of the study. The year and a half long trial will conclude just before the summer of 2022. We're delighted to be one of the first centers to begin the trial and are looking forward to seeing how the trial drug preforms in the coming months.

UC San Diego HD CoE Will Complete Triplet Study Soon

The Triplet study site here at UCSD will be completing the observational study soon. Shield-HD which is investigating how HD progresses over time is to be used to collect data to further our understanding of how mutant huntintin protein affects the brain in at-risk patients. This study is an important step in preparing researchers to take the leap into genetic modification of the mutant huntintin gene. Thank you to our study participants who already completed the study and those who are soon to be finished!

Generation HD-1 Trial Heading Toward its Last Quarter

The Generation HD-1 clinical trial, investigating the clinical trial drug RG6042, an antisense oligonucleotide, will soon be entering its last quarter. We have 16 patients currently enrolled here at our Center of Excellence, the first of which will be completing the trial at the end of this upcoming summer! As always, we will continue to support and monitor our trial patients during these last few months.

WAVE Precision-HD2 Trial Update

UC San Diego HDSA CoE has now enrolled several patients in the WAVE Life Sciences PRECISION-HD2 clinical trial. This trial focuses on a new drug targeting mutant huntingtin protein that is part of a novel generation of drugs employing antisense oligonucleotides.

UCSD Named Center of Excellence

UC San Diego is one of 47 centers nationwide to receive the prestigious designation of Center of Excellence by the Huntington's Disease Society of America, which recognizes centers for their elite multidisciplinary approach to Huntington’s disease care and research. This is the 17th consecutive year that UCSD has earned the HDSA Center of Excellence designation.